Clinical nutrition (Edinburgh, Scotland) · 2025
High "sarcopenia index" reduce all-cause mortality in patients with acute myocardial infarction.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pan Hui, Yu Dong C, Cheng Yang Z, Bin Xi Y, Lin He, Lu Zhu J, Wen Wang X, Jie Zhan H, Hao Wang Z
Аннотация
BACKGROUND: The product of serum creatinine and cystatin C-based estimated glomerular filtration rate (hereinafter referred to as "Cr × eGFRcys"), serving as the formula for the Sarcopenia Index (SI), could be regarded as a representative marker for sarcopenia. However, no studies have investigated whether Cr × eGFRcys can predict all-cause mortality in elderly patients with acute myocardial infraction (AMI).
AIM: To investigate the association between Cr × eGFRcys and all-cause mortality risk in elderly AMI patients.
METHODS: We conducted a retrospective cohort analysis of 500 elderly (≥65 years) AMI patients. Participants were stratified into high and low Cr × eGFRcys groups using the optimal cut-off determined by receiver operating characteristic (ROC) analysis, with all-cause mortality as the primary endpoint. Kaplan-Meier (hereinafter referred to as "K-M") survival curves assessed survival differences (log-rank test). Multivariable Cox proportional hazards models evaluated the independent association of Cr × eGFRcys (as continuous, categorical, or per-standard deviation increase) with mortality. The added predictive value beyond conventional risk factors was assessed through C-statistics, continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI).
RESULT: Survival analysis revealed significantly better outcomes in the high Cr × eGFRcys group compared to the low group (log-rank p < 0.0001). Inclusion of Cr × eGFRcys significantly enhanced the predictive accuracy of the baseline risk model for all-cause mortality: NRI = 0.43 (95 % CI: 0.17-0.61, p < 0.01), IDI = 0.04 (95 % CI: 0.01-0.08, p = 0.02), and C-index = 0.93 (95 % CI: 0.90-0.96), all with p < 0.05.
CONCLUSION: Cr × eGFRcys was significantly associated with all-cause mortality, and the optimal cut-off value for predicting all-cause mortality was 53.56, suggesting that Cr × eGFRcys may serve as a valid marker of all-cause mortality in elderly patients with AMI.
AIM: To investigate the association between Cr × eGFRcys and all-cause mortality risk in elderly AMI patients.
METHODS: We conducted a retrospective cohort analysis of 500 elderly (≥65 years) AMI patients. Participants were stratified into high and low Cr × eGFRcys groups using the optimal cut-off determined by receiver operating characteristic (ROC) analysis, with all-cause mortality as the primary endpoint. Kaplan-Meier (hereinafter referred to as "K-M") survival curves assessed survival differences (log-rank test). Multivariable Cox proportional hazards models evaluated the independent association of Cr × eGFRcys (as continuous, categorical, or per-standard deviation increase) with mortality. The added predictive value beyond conventional risk factors was assessed through C-statistics, continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI).
RESULT: Survival analysis revealed significantly better outcomes in the high Cr × eGFRcys group compared to the low group (log-rank p < 0.0001). Inclusion of Cr × eGFRcys significantly enhanced the predictive accuracy of the baseline risk model for all-cause mortality: NRI = 0.43 (95 % CI: 0.17-0.61, p < 0.01), IDI = 0.04 (95 % CI: 0.01-0.08, p = 0.02), and C-index = 0.93 (95 % CI: 0.90-0.96), all with p < 0.05.
CONCLUSION: Cr × eGFRcys was significantly associated with all-cause mortality, and the optimal cut-off value for predicting all-cause mortality was 53.56, suggesting that Cr × eGFRcys may serve as a valid marker of all-cause mortality in elderly patients with AMI.